GPP is a chronic-relapsing and potentially life-threatening disorder and is considered a phenotype of pustular psoriasis. It presents with multiple coalescing sterile pustules on erythematous skin; patients may also have fever, malaise, high white blood cell counts, and elevated C-reactive protein (CRP). It can also appear as arthritis, acute respiratory distress syndrome, cholestasis, and neutrophilic cholangitis. Because it is so rare, data from larger, high-quality clinical studies are not available, the authors wrote.

Researchers analyzed medical records from January 2005 to May 2019 containing information about 201 treatment series from 86 patients with GPP. Those who had exclusive treatment with systemic glucocorticoids or phototherapy were excluded, as were patients with 1 prior course of treatment with anakinra but who then switched to secukinumab; or with brodalumab who then switched to ustekinumab.

Overall, 65.1% of the patients were female, with an average age of 51.2 years when GPP began; they had a mean disease duration of 8.7 years. Laboratory results from their first visit to a medical center showed elevated CRP in just over 75% of the patients; 62.4% had leukocytosis; 38.1% had an electrolyte imbalance; other patients had hypocalcemia, hypo- or hyperkalemia, or hyponatremia.

Additional characteristics stemming from flare-related complications that indicated the severity of the disease included:

Additionally, nearly 13% of the patients needed admission to an intensive care unit or other intensive care due to a GPP flare; 74.1% of patients had evidence of disease at the time of their last visit.

Patients had received an average 2.3 systemic therapies for GPP. Psoriatic vulgaris was diagnosed in 50.0% and psoriatic arthritis in 17.4% of the patients.

Overall, an excellent response was reached in 41.3% of all treatment courses, and a partial response was seen in 31.4%. Nonresponse occurred in 27.3% of treatment courses.

Biological treatment was significantly more effective than nonbiological therapies, with biologics seeing an excellent response in 47.4% of treatment series compared with 35.9% of nonbiologics (P = .02). Overall, the median drug survival was 14 months (36 months for biologics vs 6 months for nonbiologics; P <.001).

Inhibitors of interleukins 17A and 23 showed particularly strong efficacy and drug survival, the researchers said, and should be considered earlier in the course of the disease. They noted that in Japan, guidelines on GPP recommend biologics and antitumor necrosis factor agents for GPP; in Germany, corticosteroids and acitretin are the only licensed drugs for GPP.

The crude probability of drug survival was highest for secukinumab (HR of drug discontinuation compared with acitretin, 0.22), followed by ixekizumab and ustekinumab (HR, 0.38 each).

This study is one of the larger case series adding to the growing evidence on treatment of GPP and, to our knowledge, is the first in-depth analysis of drug survival in GPP in a real-life setting, the researchers wrote.

Reference

Kromer C, Loewe E, Schaarschmidt ML, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. Published online January 26, 2021. doi:10.1111/dth.14814

Continued here:

Rare, Severe Type of Psoriasis Merits Biologic Consideration, Researchers Say - AJMC.com Managed Markets Network

Raynauds syndrome, also known as Raynauds phenomenon, is a condition that affects body extremities such as the fingers.

In response to a trigger like cold air or emotional stress, blood vessels become narrow and normal circulation is cut off. This can make your fingers very pale or blue, tingly, or numb. Raynauds can also sometimes affect other areas like your toes, nose, and ears.

Raynauds syndrome has been associated with certain autoimmune diseases.

Psoriatic arthritis (PsA) is a chronic, inflammatory autoimmune condition. It affects the joints and surrounding areas where the bone connects to ligaments and tendons. It can occur at any age but often develops between ages 30 and 50.

If you have PsA, you may be wondering if you should be looking out for signs of Raynauds syndrome. Read on for more information about the two conditions.

While PsA is a type of autoimmune disease, research supporting a direct correlation between PsA and Raynauds is limited. Theres not much evidence to show that the two conditions are related.

However, its possible to have both conditions.

If you experience symptoms of cold intolerance and color changes of your fingers or toes, a rheumatologist can perform tests to determine whether or not those symptoms are consistent with Raynauds.

This diagnostic process may include:

Certain factors can increase your chance of developing Raynauds phenomenon. They include:

Raynauds syndrome has been linked to another inflammatory type of arthritis called rheumatoid arthritis. Still, Raynauds is less common in rheumatoid arthritis compared with other types of rheumatic diseases, such as lupus.

Raynauds phenomenon is a type of vasculitis. The sudden narrowing of the arteries in your fingers or other extremities is called vasospasm, and it happens in response to triggers like cold and anxiety.

Over time, people who have been living with rheumatoid arthritis may develop vasculitis. Where rheumatoid arthritis affects the joints, vasculitis causes inflammation in the blood vessels. This affects blood flow to certain areas of your body.

Vasculitis can cause artery walls to become inflamed, which narrows the passage through which your blood travels.

PsA treatment depends on the frequency and severity of symptoms you experience. Mild, intermittent PsA symptoms can be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, taken as needed.

More severe cases of PsA are treated with stronger medications like disease-modifying anti-rheumatic drugs (DMARDs) and biologics, or even surgery.

Treatment for Raynauds is different from PsA treatment and depends on the type. There are two types of Raynauds: primary and secondary.

Known as Raynauds disease, the primary form of Raynauds occurs without any associated medical conditions. Blood work is often normal with no indicators that anything is out of the ordinary.

Primary Raynauds can usually be managed with self-care measures. These include:

In some cases, Raynauds is the first sign that another underlying condition is present. Known as Raynauds syndrome or phenomenon, the secondary form of Raynauds is thought to occur as the result of an autoimmune-related condition, such as:

Secondary Raynauds is often more severe and can require more intervention to manage. It can cause pain and even result in complications like skin ulcers and gangrene. Its less common than primary Raynauds and usually occurs in people over 30 years of age.

Secondary Raynauds can benefit from lifestyle changes as well. However, its often most improved when the underlying condition is treated.

Other treatments specifically for Raynauds aim to prevent tissue damage like ulcers. These include:

PsA is an inflammatory, autoimmune type of arthritis that can accompany psoriasis. Raynauds phenomenon is a type of vasculitis, or narrowing of the blood vessels.

Both conditions are a result of an overactive immune system, which triggers inflammation in the body.

Research supporting a direct link between PsA and Raynauds is limited, but its possible to have both conditions. If you experience Raynauds symptoms, talk to your rheumatologist.

View post:

Psoriatic Arthritis and Raynaud's Syndrome: The Link - Healthline

Arthritis is a painful rheumatic condition that causes joint inflammation. There are many different types of arthritis that can affect the joints and other areas of the body and cause similar symptoms, such as pain, swelling, and stiffness.

There are more than 100 different types of arthritis. Some common types of arthritis include osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA).

Below, we explore these conditions, as well as other diseases that can present with arthritis. We also discuss potential treatment and when to seek medical guidance.

According to the Centers for Disease Control and Prevention (CDC), OA affects over 32.5 million adults in the United States.

Symptoms of OA include:

People often experience OA symptoms in the hips, hands, and knees.

The following increase the likelihood of developing OA:

Learn more about OA here.

RA is an autoimmune condition that causes painful swelling and inflammation in the joints. It typically affects the hands, wrists, and feet.

RA does not only affect joints. It can also cause problems in other organs of the body, including the heart, lungs, and eyes.

While some people experience a sustained progression of the disease, the intensity of symptoms usually comes and goes. Symptoms may include:

Another characteristic of RA is symmetrical involvement. This means pain and signs of inflammation occur on both sides of the body and in the same joints.

RA can cause lasting tissue damage, which can lead to:

Some people who have RA may also need assistance walking.

Some RA risk factors include:

Learn more about RA here.

PsA is an autoimmune condition.

Symptoms of PsA include:

PsA joint involvement is asymmetric, affecting different joints on either side of the body.

This type of arthritis can develop in people with a skin condition called psoriasis, which causes scaly, flushed, or silvery patches of skin. These patches can look different depending on a persons skin color.

Learn more about psoriasis on black skin here.

Researchers still do not fully understand what causes this form of arthritis. However, having a family history of PsA may increase a persons risk of developing this condition.

Learn more about PsA here.

Gout is a type of arthritis that causes painful swelling, often in a single joint at a time.

Symptoms of gout can flare up and go away quickly. They include:

Swelling is common in the big toe. Often, it also affects the knee or ankle joint.

A person may be at higher risk of developing gout if they:

Health conditions that may lead to gout include:

Gout may also occur due to metabolic syndrome, which is not a condition in itself. It refers to a number of characteristics, diseases, or habits that can make a person more likely to experience other health conditions, such as heart disease, stroke, or diabetes.

Learn more about gout here.

This chronic illness is an autoimmune condition that commonly affects females aged 1544 years.

Lupus is not a type of arthritis in itself. However, arthritis is one of the most common symptoms of this condition.

One symptom of lupus is the characteristic butterfly rash that can develop on the face. Other rashes can also develop on the arms, hands, and face. Rashes can worsen after sun exposure.

While symptoms may differ from person to person, they generally include:

Learn more about lupus here.

Juvenile arthritis, also known as childhood arthritis, affects children or even infants.

Symptoms of juvenile arthritis include:

There is no known cause of childhood arthritis. It appears to affect children regardless of race, age, or background.

Learn more about juvenile arthritis here.

Reaching a definitive diagnosis may take time, because many types of arthritis are similar or resemble other conditions.

Typically, a doctor will first check a persons medical and family history. They will also ask about symptoms and perform a physical exam. They may run tests such as:

Arthritis management depends on the type of arthritis. There are different forms of treatment available.

Medical treatment for arthritis may involve:

Surgery may not be necessary for everyone with arthritis. However, it can benefit certain complications of arthritis that result in malalignment of joints and functional limitations due to damaged joints. It can also help with intractable pain, which is when a person experiences pain that is difficult to treat or manage.

Common surgeries for arthritis include:

Physical therapy can be a great option for people with arthritis. It can help ease pain or increase activity.

Behavioral changes that can help with arthritis may include:

Some people find certain home remedies helpful in relieving pain and swelling from certain types of arthritis. These may include:

If a person has experienced joint symptoms that last more than 3 days, they should seek treatment from a healthcare professional.

Similarly, if a person has joint symptoms at different times within a month, they should also contact a doctor.

Medications and other treatments can help a person manage chronic symptoms, such as pain and swelling.

Pain will come and go with many types of arthritis. However, even if the pain resolves, a person should still seek treatment.

It is important to treat arthritis early. If left untreated, some types of arthritis may worsen over time and cause permanent disability.

Arthritis is a painful condition that causes joint inflammation.

Different types of arthritis can cause similar symptoms. It is vital to get the correct diagnosis, as it can help determine most effective treatment options.

The right treatment may also prevent future complications and help a person live a more active life.

See original here:

Common types of arthritis: Location, causes, treatment, and more - Medical News Today

- The British Journal of Dermatology has publishedevidence of sustained efficacy in tildrakizumab responders and a favourable long-term safety profile with total tildrakizumab exposure of over 5400 patient-years through 5 years (256 weeks)[1]

- The full complete pooled dataset demonstrates long-term psoriasis control with tildrakizumab with a consistent long-term safety profile through 5 years (256 weeks)[1]

- This is the first and longest complete pooled dataset published in a medical journal on an anti-IL23p19 inhibitor

BARELONA, Spain, Feb. 9, 2021 /PRNewswire/ -- Almirall, S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today that the British Journal of Dermatology (BJD) has published a full 5-year pooled data analysis from two phase III clinical studies, reSURFACE 1 and reSURFACE 2 of Ilumetri (tildrakizumab), an IL-23p19 inhibitor for the treatment of moderate-to-severe plaque psoriasis, and can be found in the BJD online library. These data provide evidence of sustained efficacy in tildrakizumab responders and in patients switched from etanercept to tildrakizumab at week 28, and a favourable long-term safety profile with total tildrakizumab exposure of over 5400 patient-years. During this period, PASI and PGA response rates were maintained in a large proportion of patients[1]. This is the first and longest complete dataset published in a medical journal on an anti-IL23p19 inhibitor.

Long-term efficacy and safety: up to 5-year results from reSURFACE 1 and reSURFACE 2[1]

Results of the 5-year pooled data from reSURFACE 1 and reSURFACE 2demonstrated long-term control of psoriasis, with a large proportion of patients who responded at week 28 maintaining efficacy by both relative and absolute PASI. Absolute PASI <3 at week 244 for tildrakizumab 100mg and 200mg were 78.8% and 82.6% respectively. PGA 0/1 at week 244 for tildrakizumab 100mg and 200mg were 68.5% and 74.2%, respectively (multiple imputation for missing data). Results show a favourable long-term safety profile with a total tildrakizumab exposure of over 5400 patient-years. Both 100mg and 200mg doses weregenerally well tolerated with low rates of serious adverse events and adverse events of special interest through 5 years.

"In our study, patients who responded to tildrakizumab maintained a clinically significant response over 5 years. Control of psoriasis was sustained with a reassuring safety profile. This tildrakizumab study confirms the role that the IL23p19 class can play in achieving long term control for our psoriasis patients," stated Prof Diamant Thai, Director of the Comprehensive Centre for Inflammation Medicine at Lbeck University in Germany, the first author of the study.

Safety was further explored in different analyses examining incidence rates of severe infections, malignancies, and major adverse cardiovascular events, as well as overall safety in patients over 65 years of age. No new reported signals were found in any of the sub-groups.

About tildrakizumab[2]

Tildrakizumab is a humanized monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23) and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Tildrakizumab demonstrated superiority vs placebo and etanercept in the phase 3 reSURFACE programme. Significantly more tildrakizumab patients achieved PASI 75 at Week 12 vs. placebo in both studies [re-SURFACE-1/2: 64%/61% (100 mg), 62%/66% (200 mg) vs 6%/6% (PBO), p<0.0001] and vs. etanercept [reSURFACE-2: 61% (100 mg, p=0.001), 66% (200 mg, p<0.0001) vs 48%]. Significantly more tildrakizumab patients achieved a PGA score of 'clear' or 'minimal', with 2-grade reduction from baseline at Week 12 in both studies vs. placebo [re-SURFACE-1/2: 58%/55% (100 mg), 59%/59% (200 mg) vs 7%/4% (PBO), p<0.0001], TIL 200 mg (59%, p=0.0031) and TIL 100 mg (55%, p=0.0663) vs. ETA (48%). The incidence of severe infections, malignancies, and major adverse cardiovascular events seen in the clinical trials were low and similar across treatment groups, with the most common AE being nasopharyngitis. Tildrakizumab was administered as 100 or 200 mg injection(s) at week 0 and 4 in the induction phase and then every 12 weeks thereafter for maintenance. DLQI 0/1 at week 12 was achieved by 42% of patients (n=309); by week 28 it was achieved by 52% of the patients (n=299) with patients reporting that psoriasis no longer affected their lives. By week 52, 64% of the responders at week 28 achieved DLQI 0/1 (n=113).

Almirall in-licensed Tildrakizumab from Sun Pharmaceutical Industries Ltd. (Sun Pharma) in July 2016. The agreement is for development and commercialization of tildrakizumab in Europe. So far, tildrakizumab has been launched in Germany, United Kingdom, Switzerland, Austria, Denmark, Spain, Italy and France.

References

1. Thai D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021 Feb 5. doi: 10.1111/bjd.19866.

2. IlumetriI (tildrakizumab) Summary of Product Characteristics.

Logo - https://mma.prnewswire.com/media/1217694/Almirall_Logo.jpg

https://www.almirall.com/

SOURCE Almirall, S.A.

See original here:

Almirall announces a new publication in the British Journal of Dermatology of ILUMETRI (tildrakizumab) as the first anti-IL23p19 treatment for which...

Dr. Mikita

Our skin is one of our hardest working organs. It not only protects all the other organs in our bodies, and can repair itself, but it also regulates body temperature and detects and fights off infection. Healthy skin is an essential part of your overall health and wellness, yet most of us take our skin for granted, especially in the winter.

Winters

Effects

on Skin

Frequent hand washing and sanitizer use may already be taking a toll on your hands as the pandemic continues, but as temperatures and humidity levels continue to drop, other body parts can also get itchy, cracked, and irritated.

The harsh weather can strip the skins natural protective barrier, creating gaps in the outer most layer, allowing water to escape promoting dehydration and irritants to get in. The dry environment may be responsible for that uncontrollable itch, as the inflammatory response kicks in and releases histamines. It can exacerbate inflammatory skin diseases such as rosacea, eczema, ichthyosis, and psoriasis, which suffer an impaired barrier function.

Tips to Avoid a Painful

Season

If you are not prepared, the changes to your skin can make for a long winter. Knowing how your skin typically reacts to cold weather can help you create a routine ahead of time and keep your skin from reacting negatively to fall and winter.

Know Your Skin: As winter approaches, try to remember how your skin changed during past winters. Maybe your skin stayed the same as it did in the summer. This could be because of the routine you have in place. If your skin changed and became dryer than usual, this may mean you need to better prepare your skin for winter.

If you know your skin is prone to drying out from cold weather, a way to prepare your skin before and during the winter is to stick to short and warm showers. Long, hot showers can feel great after a cold day, but can strip your skin of important oils, leaving it dry.

Its All About Moisture: Find a good moisturizer and use it before the cold weather hits and throughout the cold weather season. A moisturizer does exactly what its name implies: moisturizes. Moisturizing your skin in preparation for the cold weather and during the winter can help your skin from becoming dried out. An oil-free moisturizer that contains glycerin is best to help keep skin hydrated.

Some Conditions Require Special Treatment: If you have eczema or psoriasis, you will have to do more than simply slather on extra lotion and drink more water.

In the case of eczema, your body overreacts to an external trigger, such as dust mites or perfumes in cosmetics and soaps. Eczema develops as itchy, red skin, often in areas where skin touches skin, such as in the bends of the arms or knees. If you have eczema, its important to use fragrance-free, hypoallergenic soap and moisturizers, as fragrances can cause allergies and further trigger itchiness and inflammation. One over-the-counter cream that may help provide relief from symptoms. You should also use scent-free hypoallergenic laundry detergent for the same reason. Certain fabrics, such as those made with wool, may be irritating to delicate skin as well.

In the case of psoriasis, a hyperactive immune response causes new skin cells to proliferate more quickly than old ones can be shed. The result is that cells pile up on top of each other, causing red patches with silvery scales. Psoriasis almost always requires prescription treatment because of the underlying autoimmune disease, but the best option varies depending on how much of the skin is impacted. Lack of sun exposure during winter months can also have an effect on psoriasis so your provider may consider phototherapy, a treatment that essentially involves using a light box to expose skin to controlled amounts of UV light in order to dampen inflammation.

Preparation Can Go a Long Way

Dry skin can make for an uncomfortable winter which is why preparation is key as we continue through the cold winter months. If youre having trouble managing your skin care, talk to a dermatologist. Your dermatologist can help you develop a routine and care plan to meet your skins unique needs. If youre experiencing severely dry or chapped skin, or if youve recently developed a rash thats not improving, talk to your doctor as these could be signs of a dermatologic condition or symptoms of more serious illness or allergic reaction.

Dr. Sabrina Mikita is a dermatologist with UPMC seeing patients at SH Dermatology located at 1205 Grampian Blvd., Suite 1A, Williamsport. For more information or to schedule an appointment, call 570-326-8060.

Today's breaking news and more in your inbox

Read more:

Tips to prevent cold weather skin issues | News, Sports, Jobs - The Express - Lock Haven Express

Highmark, a Blue Cross Blue Shield-affiliated health insurer, will expand access to Freespira's digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms.

In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespirato those not already receiving support from a behavioral health professional, according to the announcement.

"We are pleased with the clinical and financial outcomes achieved for our health plan members through the use of Freespira," Demetrios C. Marousis, director of behavioral health at Highmark, said in a statement.

"This breakthrough, drug-free treatment has reduced the impact of symptoms associated with panic attacks, resulting in reduced use of medications and other healthcare costs for symptom management. Freespira adds value to our members' plans and helps us to create a remarkable health care experience, freeing people to be their best."

Barcelona-based biopharma company Almirall and New York-based Happify Health will be working together to develop an international version of Claro, a digital treatment that addresses the mental health of psoriasis patients. This product would be designed for psoriasis patients living in Spain, Italy, France and the U.K., and would be deployed later this year through the Almirall patient support program.

"Since mental health events act as stressors that can trigger psoriasis flare ups, Happify is excited to work with a European leader like Almirall in this condition to address the mental and physical health symptoms of these patients," Chris Wasden, head of digital therapeutics at Happify Health, said in a statement.

"Our digital therapeutic solution acts as a complement to Almirall's commitment to psoriasis patients to empower people with psoriasis to live full lives through meaningful behavior change. Together, we can help psoriasis patients, one patient at a time, and at scale."

Kaiser Permanente has signed a multi-year collaboration with Accenture and Microsoft to bring more of its digital ecosystem to the cloud. The healthcare provider said that the partnership will enable new capabilities for Kaiser Permanente members and clinicians alike for more personalized and accessible care.

This collaboration will help Kaiser Permanente better serve our members by providing our care teams with increased access to cloud-based services, which will enable them to deliver personalized digital experiences and make more data-informed decisions, Diane Comer, SVP and interim CIO for Kaiser Permanente, said in a statement.

Boehringer Ingelheim's representatives will be using air quality data from BreezoMeter when speaking with clinicians about their patients' respiratory health, the pharma company announced last week. By tapping both real-time and historical data, Boehringer would be able to help predict when and whether environmental stressors could exacerbate symptoms of asthma, COPD and other conditions, and thereby raise awareness among providers.

"We complement our commitment to developing innovative therapies by developing innovative digital solutions with the goal of supporting healthcare providers in managing chronic conditions, Jim Boushie, executive director of business transformation at Boehringer Ingelheim, said in a statement.

To improve respiratory health and treatment plans, we utilize BreezoMeters data to help expose the effects of high pollution and pollen. Their air quality analytics empower our teams and will continue to inform how we collaborate with physicians to improve patient outcomes.

Otsuka Pharmaceutical's Development & Commercialization arm has partnered with Spencer Health Solutions, the maker of an at-home medication adherence platform, to further evaluate and deploy direct-to-patient services through the device. In particular, the pharma company said it will be considering the device's medication adherence and patient engagement capabilities in upcoming traditional and decentralized clinical trials.

Our commitment to the democratization of clinical trials, patient engagement and leveraging technology to improve diversity and inclusion in clinical research helps drive our success at Otsuka, Dr. Christoph Koenen, EVP and chief medical officer at Otsuka Pharmaceutical Development & Commercialization, said in a statement.

The spencersmart hub will be an asset in our efforts to improve treatment plans for people living with challenging health conditions.

Originally posted here:

Highmark expands access to Freespira's DTx, Almirall and Happify developing digital mental health program for European psoriasis patients and more...

Our skin is one of our hardest working organs. It not only protects all the other organs in our bodies, and can repair itself, but it also regulates body temperature and detects and fights off infection. Healthy skin is an essential part of your overall health and wellness, yet most of us take our skin for granted, especially in the winter.

Winters Effects on Skin

Frequent hand washing and sanitizer use may already be taking a toll on your hands as the pandemic continues, but as temperatures and humidity levels continue to drop, other body parts can also get itchy, cracked, and irritated.

The harsh weather can strip the skins natural protective barrier, creating gaps in the outer most layer, allowing water to escape promoting dehydration and irritants to get in. The dry environment may be responsible for that uncontrollable itch, as the inflammatory response kicks in and releases histamines. It can exacerbate inflammatory skin diseases such as rosacea, eczema, ichthyosis, and psoriasis, which suffer an impaired barrier function.

Tips to Avoid a Painful Season

If you are not prepared, the changes to your skin can make for a long winter. Knowing how your skin typically reacts to cold weather can help you create a routine ahead of time and keep your skin from reacting negatively to fall and winter.

Know Your Skin: As winter approaches, try to remember how your skin changed during past winters. Maybe your skin stayed the same as it did in the summer. This could be because of the routine you have in place. If your skin changed and became dryer than usual, this may mean you need to better prepare your skin for winter.

If you know your skin is prone to drying out from cold weather, a way to prepare your skin before and during the winter is to stick to short and warm showers. Long, hot showers can feel great after a cold day, but can strip your skin of important oils, leaving it dry.

Its All About Moisture: Find a good moisturizer and use it before the cold weather hits and throughout the cold weather season. A moisturizer does exactly what its name implies: moisturizes. Moisturizing your skin in preparation for the cold weather and during the winter can help your skin from becoming dried out. An oil-free moisturizer that contains glycerin is best to help keep skin hydrated.

Some Conditions Require Special Treatment: If you have eczema or psoriasis, you will have to do more than simply slather on extra lotion and drink more water.

Preparation Can Go a Long Way

Dry skin can make for an uncomfortable winter which is why preparation is key as we continue through the cold winter months. If youre having trouble managing your skin care, talk to a dermatologist. Your dermatologist can help you develop a routine and care plan to meet your skins unique needs. If youre experiencing severely dry or chapped skin, or if youve recently developed a rash thats not improving, talk to your doctor as these could be signs of a dermatologic condition or symptoms of more serious illness or allergic reaction.

Dr. Sabrina Mikita is a dermatologist with UPMC seeing patients at SH Dermatology located at 1205 Grampian Blvd., Suite 1A, Williamsport. For more information or to schedule an appointment, call (570) 326-8060

Excerpt from:

UPMC doctor: tips to prevent cold weather skin issues - NorthcentralPa.com

Having lived through a global pandemic for going on a year now, weve learned a lot, like that face masks are important, toilet paper is a hot commodity, and the world of exotic animals is far wilder than we could have possibly imagined. And while all (*gestures wildly*) of that was going on, we still managed to learn a lot about skin care while social distancing at home as well.

As many of us used the time at home to recalibrate our beauty routines, we relied on some of our favorite dermatologists to help us do it properly. Over the course of the pandemic, Well+Good has published hundreds of stories about skin care, ranging from how to deal with maskne (a word none of us had ever even heard before 2020) to how to treat psoriasis with a $10, over-the-counter lotion. To find out which tips have made the biggest difference in our skin during this unusual year, keep on scrolling.

Cleansing oil is known to be one of the gentlest, most effective types of face wash that works for all skin types, but in order to reap its full benefits, youve got to use it properly. According to derms, you should start by applying it to dry skin, which will better help it pick up the makeup, dirt, and oil from your pores, massage it in circular motions, then rinse it off entirely with warm water (never cold, because it will solidify the oil) to ensure it gets off all the gunk.

Adult acne is very much a thing, which means that when youre trying to treat it, you also may be trying to treat fine lines and wrinkles. The fix, according to board-certified dermatologist Joshua Zeichner, MD, is to use a simple two-ingredient combo. You need to make sure that the acne products are in line with other aesthetic needs of the patients, he says. Thats where topical retinoids are really helpful, and ingredients like salicylic acid, because they both give exfoliating benefits, and skin brightening and evening benefits, and retinoids can also help to stimulate collagen production.

There are plenty of effective hydrating ingredients out there (in the video above, board-certified dermatologist Mona Gohara, MD, names five of them), but the one that unquestionably deserves a spot in any no-frills routine is glycerin. Humectants attract water to the skin, explains Dr. Gohara, adding that glycerin and other fan-fave hydrator hyaluronic acid both fall into this category. And glycerin is not only so great at drawing water into the skin, but its also super gentle, which is why youll see it in a ton of products. I personally think that glycerin is the one ingredient thats good for everyone. Its no bells and whistles, we know it works, and everybody should have it.

There are certain serumslike the Skinceuticals legendary vitamin C serumthat are worth spending big bucks on. But others? Not so much. According to Dr. Gohara, its A-okay to skimp on other spots in your routine. When it comes to splurging, think about antioxidants, retinol, and any specific skin concern that you may have, she says. But I definitely think a gentle cleanser, a sunscreen, or even a moisturizer are places where you can save. This way, you can save up for one whizzbang treatment that really works.

Toner is one of the skin-care worlds most confusing routine steps, and derms have differing opinions on whether you really need it or not. The trick to getting the most out of it? Only apply it to certain spots. If you feel like you need it, just use it on areas where you may need a little extra love on your skin, says Dr. Gohara. If you have dry patches, look for a hydrating toner with hyaluronic acid, like Vichy Puret Thermale ($18) and if youre oily in certain spots, use an exfoliating AHA-packed option, like Glossier Solution ($24)

Last year gave us a swift introduction to the trials and tribulations of maskne, but (thankfully) also taught us how to treat it. Wearing masks is essential, but so is taking care of your skin, because thats the barrier between us and whats happening in the outside world, says Dr. Gohara. So to whatever extent you can, keep it gentle and basic. She suggests using a hydrating cleanser, likeLa Roche-Posay Toleriane Hydrating Gentle Face Cleanser ($15) to keep your skin extra clean, then applying an emollient moisturizer like Vaseline($2) orCerave Healing Ointment ($10) to the bridge of your nose, around your ears, jawline, cheekbones, and anywhere else where the mask might be rubbing.

Dont pick your skin is the skin-care advice dermatologists dish out on the reg and that most of us constantly ignore. If you are going to go all-in on your blackheads (which, same), Dr. Gohara says theres only one right way to go about it. One of the most important ways to get rid of blackheads is to extract them out, says Dr. Gohara. Im not giving you the carte blanche to go at them with your nails, but I definitely think there are ways we need to extract blackheads. Shes a fan of using at-home comedone extractors, like this one, which are a whole lot safer for your skin than your own fingers.

Considering this year forced us to spend time away from our dermatologists offices, we had to find at-home solutions for the treatments we often rely on them on. And in the case of Botox, we turned to collagen-stimulating peptides to help keep our skin plump. Peptides are small amino acids, which are the building blocks of collagen, explains Dr. Gohara. Kind of like a grape is to wine, peptides are to collagen. They wake up the collagen, shake it up a little bit, so it knows it has to produce itself more. The result? Smoother, juicier skinno needles required.

2020 was the year that I learned that those little pimple-looking spots on my butt werent actually pimples at all. One of the most common things that my patients come in forwhich can be very distressingare pimple-like lesions on the butt. Or, buttne, says Dr Gohara. But in reality, it aint buttne at all. While the blemishes on your behind maylook like red, angry, inflamed zits, theyre actually something different entirely. These arent true pimplestheyre inflamed hair follicles, explains Dr. Gohara. To deal with them, she suggests using a 1.5 or two percent benzoyl peroxide wash in the shower, like Panoxyl Acne Foaming Wash ($9). If that doesnt work, it may be time to take a trip to the dermatologist for a more intense prescription treatment.

Treating psoriasis can be frustrating, but it doesnt have to be expensive. According to Dr. Gohara, the best OTC treatment will only run your $10. Her go-to?Eucerin Advanced Repair Lotion($10). It has a smidge of exfoliators in it, so its a nice compromise between total exfoliation and just moisturizing, she says. Its made with lactic acid, which will help to gently slough away flakes, andceramides, which work to strengthen your skin barrier. I think that would be a very nice choice for somebody who has psoriasis on their skin, says Dr. Gohara.

Want even more beauty intel from our editors? Join Well+GoodsFine Print Facebookgroup (and follow us onInstagram) for must-know tips and tricks.

Read more here:

If Youre Going to Follow Any Pandemic-Era Skin Care Advice, Derms Say to Make It This - Well+Good

Spondyloarthritis is an umbrella term that describes different types of arthritis. These types mainly affect the spine, but they can also cause symptoms in other parts of the body.

There has been some debate about whether spondyloarthritis is an autoimmune condition or an autoinflammatory condition. However, recent research suggests that spondyloarthritis is indeed an autoimmune condition.

This article will explore spondyloarthritis in detail. Specifically, it will examine the different types, symptoms, and treatment options associated with the condition.

There are several subtypes of spondyloarthritis. Each can involve a different part of the body.

The following sections will look at some of these types in more detail.

Ankylosing spondylitis is the most common form of spondyloarthritis. It involves ligaments, tendons, and joint capsules attaching to bones in the spine and peripheral joints.

It can cause the bones in the spine to fuse together, leading to stiffness and immobility.

Learn more about ankylosing spondylitis here.

This type of spondyloarthritis primarily involves the joints in the spine and pelvis.

Axial spondyloarthritis causes back pain and affects around 5.5 million people in the United States.

Like axial spondyloarthritis, the non-radiographic form also affects the spine and causes lower back pain.

However, the effects of non-radiographic spondyloarthritis are not visible on X-rays. They are only visible on more sensitive imaging tests, such as MRI scans.

Peripheral spondyloarthritis describes a number of spondyloarthritis subsets.

It mainly affects the hands and feet. However, it can also cause inflammation in the:

Both rheumatoid arthritis and spondyloarthritis are very common. Although they share some similarities, the conditions also have significant differences.

Spondyloarthritis tends to be more common in males, whereas rheumatoid arthritis is more common in females.

Rheumatoid arthritis symptoms typically start appearing when a person is around 4050 years of age. The symptoms of spondyloarthritis usually occur earlier than this.

The early symptoms of rheumatoid arthritis usually affect the hands and feet. The early symptoms of spondyloarthritis usually start with back pain.

Learn more about the early signs and symptoms of rheumatoid arthritis here.

People often develop spondyloarthritis in their teenage years or 20s. Those with the following characteristics may be more likely to experience spondyloarthritis:

It is important to note that spondyloarthritis is notoriously difficult to diagnose in females. This could mean that it is more common in females than some statistics may show.

Lower back or hip pain is a common early symptom. However, symptoms can vary depending on the type of spondyloarthritis a person has.

Inflammation elsewhere in the body is a symptom of spondyloarthritis. It can especially affect the:

Spondyloarthritis-related inflammation can cause:

Another symptom of spondyloarthritis and the swelling it causes is psoriatic rashes. These may appear differently depending on a persons skin color.

Learn more about psoriasis on black skin here.

These symptoms may be particularly painful first thing in the morning or after periods of rest.

Untreated spondyloarthritis could lead to a person developing the following conditions:

A person who is experiencing symptoms of spondyloarthritis should contact a doctor to treat the condition. This may help prevent these complications.

If a person has had chronic lower back pain since before the age of 40 years, they may have spondyloarthritis. People often assume that they simply have back pain due to poor posture or other mechanical issues.

Because the pain can come and go, some people may assume that the pain is not important. However, not seeking treatment for spondyloarthritis can lead to complications later on.

A person who suspects that they have spondyloarthritis should contact a doctor. They should provide the doctor with details about their pain onset and whether or not they have other inflammatory symptoms that might suggest the presence of spondyloarthritis.

A doctor will diagnose spondyloarthritis by taking a persons medical history and performing a physical exam.

Imaging can help confirm a diagnosis. The doctor may request an MRI scan if an X-ray does not show damage but a person has symptoms that suggest the presence of spondyloarthritis.

A blood test is also available for the HLA-B27 gene, which is a gene associated with the condition. However, testing positive for the gene does not necessarily mean that a person has spondyloarthritis.

The doctor can also perform ESR tests or CRP tests on the blood in order to determine if swelling is present in the body. This can also help diagnose spondyloarthritis.

The doctor may also choose to carry out a complete blood count, to diagnose anemia, or a metabolic panel, to analyze a persons kidney and liver function.

Sometimes, medical professionals can mistake spondyloarthritis for other similar conditions, which can delay diagnosis and treatment. This is especially the case among females.

There is currently no cure for this condition. However, treatment can help relieve the symptoms and slow the progress of the condition.

Some treatment options include:

Biologics are very effective but expensive. These drugs can also increase a persons risk of infection.

Also, physical therapy can help restore range of motion in the affected joints.

One 2020 study involved putting 100 people with axial spondyloarthritis, non-radiographic axial spondyloarthritis, or psoriatic arthritis with axial involvement on physical therapy treatment programs.

The therapy significantly improved the pain that the condition caused, including among those with secondary conditions such as fibromyalgia.

Occupational therapy can also help a person improve or maintain their ability to perform day-to-day activities. An occupational therapist can provide recommendations and assistive devices to help prevent further injury.

Living with spondyloarthritis can make performing certain everyday tasks more difficult, but it is possible to manage the symptoms. Also, the condition does not usually affect a persons life expectancy significantly.

Symptoms such as pain and fatigue may come and go, and treatments can help a person live with this condition.

Some behavioral changes can also make living with spondyloarthritis easier. These changes include:

There are also spondyloarthritis support groups available for people who may need additional support.

Not seeking treatment for spondyloarthritis can lead to complications. Joints can fuse, for example, which may cause severe stiffness or immobility.

The symptoms of spondyloarthritis can come and go. However, even if a person does not constantly experience symptoms, they should still contact a doctor.

Not seeking treatment can lead to more complications of the condition. For example, it could become increasingly painful.

With the right treatment, people with spondyloarthritis can live an active life. Although there is no way to cure the condition, it is possible to manage the symptoms and prevent disease progression.

Making certain behavioral changes and trying medical treatments can make the pain and inflammation of spondyloarthritis more manageable.

Read more:

Spondyloarthritis: Types, symptoms, treatment, and more - Medical News Today

Visit the News Hub

New grant to fund research into drugs that showed promise in small study of people with Crohns disease

Meals prepared for scientific studies of metabolism and nutrition stand ready for distribution at Washington University School of Medicine in St. Louis. Researchers at the School of Medicine are studying whether drugs to treat inflammatory conditions such as Crohn's disease also could help control blood sugar levels.

Inflammation and metabolic disorders are deeply intertwined. For example, people with inflammatory conditions such as Crohns disease and psoriasis are at risk of developing metabolic disorders such as insulin resistance and diabetes. However troubling that connection might seem, it also might point to some promising news.

Researchers at Washington University School of Medicine in St. Louis have received a Catalyst grant from the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) to investigate whether immunosuppressive drugs prescribed for inflammatory bowel disease (which includes Crohns disease and ulcerative colitis) or psoriasis also can control blood sugar levels. If they do, such drugs could provide a way to improve control of blood sugar in people with inflammatory diseases, thereby reducing the risk of serious complications such as diabetes. Catalyst grants are meant to support scientists of exceptional creativity who propose pioneering and possibly transformative approaches important to the mission of the NIDDK.

The idea for the study emerged from an unexpected observation. Gwendalyn Randolph, PhD, the Emil R. Unanue Distinguished Professor of Immunology and a professor of medicine, was investigating how people with Crohns disease handle fat in their diet by feeding participants a carefully designed milkshake and monitoring the levels of different kinds of fat in their blood over time. As part of the study, the researchers also collected data on blood sugar levels. The primary result of that study was negative: People with Crohns and healthy participants processed fat much the same. But an odd pattern in the data caught Randolphs eye: The five Crohns patients who happened to be taking the anti-inflammatory drug ustekinumab maintained normal blood sugar levels after a meal, unlike other participants with Crohns disease who were taking other medications. Their glucose levels strayed higher and normalized more slowly than healthy controls.

It was really just a side observation; the study was not designed to address the question of blood glucose levels, said Randolph, the principal investigator on the $500,000 NIH grant. But this new grant will help us check it out and see if it has merit. Its an exciting hypothesis because people with inflammatory bowel disease (IBD) are at higher risk of developing metabolic disorders including type 2 diabetes, and there are not great medications to treat glucose problems linked to inflammatory disease.

As a drug that might control blood sugar, ustekinumab may be a dark horse. Scientists have speculated for years that suppressing pro-inflammatory molecules known as cytokines might help control blood sugar in people with chronic inflammation. But there are dozens of cytokines, and none of them have panned out in clinical trials. The two cytokines suppressed by ustekinumab IL-12 and IL-23 have never been high enough on the list of likely targets to warrant a study.

The serendipitous observation suggests that IL-12 and IL-23 may have previously unrecognized effects that could shine light on the complicated relationship between metabolism and inflammation.

We caught a glimpse of something, in the previous study, related to how metabolism is modified in the setting of inflammation, said co-investigator Parakkal Deepak, MBBS, an assistant professor of medicine in the Division of Gastroenterology. As a member of the medical faculty of the Inflammatory Bowel Disease Center, Deepak sees patients with IBD on the Washington University Medical Campus. With further investigation into this area, we one day may be able to select therapy for people with inflammatory diseases based on the underlying metabolic profile and the effect of specific treatments on that metabolic profile.

The researchers plan to study patients who have inflammatory diseases and already are taking drugs that target IL-12 or IL-23. With the help of the Center for Human Nutrition, the researchers will monitor levels of blood sugar and other biomolecules while participants are fasting and after meals. Bettina Mittendorfer, PhD, a professor of medicine in the Division of Geriatrics and Nutrition Sciences and an expert on glucose metabolism, is helping to design the study in people.

The researchers also are planning mouse studies to see if neutralizing IL-12, IL-23 or both improves glucose and insulin tolerance.

The implications are much larger than diabetes alone, said co-investigator Matthew Ciorba, MD, an associate professor of medicine in the Division of Gastroenterology and director of the IBD Center. There are several other important complications of IBD linked to glucose metabolism, notably nonalcoholic fatty liver disease. Understanding if current therapies can modify glucose and other metabolic complications has the potential to impact millions of patients across the world.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the article here:

Scientists to explore whether anti-inflammatory drugs control blood sugar Washington University School of Medicine in St. Louis - Washington...

Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth.

Factors that can trigger psoriasis include infections, heavy alcohol consumption, cold weather, certain medications, smoking, stress and injury to the skin such as bug bite, cut and sever sunburn. The signs and symptoms of psoriasis vary from person to person which includes dry, cracked skin that may bleed, red patches of skin covered with silvery scales, small scaling spots, itching, burning, swollen and stiff joints.

Get Sample Copy of this Report @https://www.persistencemarketresearch.com/samples/3086

Psoriasis may be classified into various types such as plaque psoriasis, scalp psoriasis, pustular psoriasis, psoriatic arthritis, guttate psoriasis, nail psoriasis, erythrodermic psoriasis and inverse psoriasis. Various treatments for psoriasis are oral medication, topical medication and biologics injections.

Psoriasis can also be treating by phototherapy treatment which includes ultraviolet light therapy, laser treatment, tanning beds, psoralen +UVA and sunlight treatment. Psoriasis can occur in any part of the body and it is associated with other health conditions such as heart disease, diabetes and depression.

North America, followed by Europe, has the largest market for systemic psoriasis therapeutics due to emergence of novel therapies and rise in treatment seeking population in the region. Asia is expected to show high growth rate in the systemic psoriasis therapeutics market in next few years due to increase in the awareness of disease in the region.

Get TOC of This Report @https://www.persistencemarketresearch.com/toc/3086

Technological advancement, rise in number of psoriasis patients, development of novel drugs, increasing disease awareness and improvement in diagnostic methods are some of the key factors driving the growth for global systemic psoriasis therapeutics market.

In addition, long-term treatment involving continuous uptake of biologics are expected to drive the market for systemic psoriasis therapeutics. However, adverse side effects associated with psoriatic drugs and economic downturns are some of the key factors restraining the growth for global systemic psoriasis therapeutics market.

Growing demographics and economies in the developing countries such as India and China are expected to offer high growth in systemic psoriasis therapeutics market in Asia. In addition, growing demand of novel therapies for psoriasis treatment is expected to develop good opportunity for global systemic psoriasis therapeutics market.

However, safety concern associated with systemic psoriasis therapeutics is expected to lead a challenge for systemic psoriasis therapeutics market. Some of the major trends that have been observed for systemic psoriasis therapeutics market are increasing use of combination therapies for treating psoriasis, emergence of non-invasive psoriasis treatment and technological advancement in the field.

Get Full Report @https://www.persistencemarketresearch.com/checkout/3086

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Read more from the original source:

Adoption By Emerging Economies To Bolster The Systemic Psoriasis Therapeutics Market Atlantic Financial Management - Atlantic Financial Management

Phototherapy, also known as light therapy, involves exposing the skin to ultraviolet light under medical supervision. Narrow-band UVB (NBUVB), Ultraviolet A (UVA)/NBUVB (in combination), and PUVA (psoralen + UVA) are the common types of phototherapy used. The choice of the type of phototherapy is dependent on the type of skin condition. However, narrow-band UVB is most widely opted due to its versatility and effectiveness for treating psoriasis, eczema, and mycosis fungoides patients across the world.

Furthermore, narrow-band UVB removes redundant and harmful UV rays by emitting wavelengths of 311-312 nm. Phototherapy equipment includes LED phototherapy equipment, fiber-optic phototherapy equipment, and conventional phototherapy equipment.

Request for a sample of this research report @https://www.coherentmarketinsights.com/insight/request-sample/1177

Rising number of psoriasis cases are expected to boost growth of the phototherapy equipment market in the near future. For instance, according to the International Federation of Psoriasis Associations (IFPA), around 150,000 new cases are reported in the U.S every year and 3% of people are affected with some form of psoriasis around the world. Furthermore, increasing number of other skin diseases is increasing the demand for LED-based phototherapy equipment such as high intensity gallium nitric blue light emitting diode, which is very effective in lowering bilirubin by providing much higher irradiance for intensive phototherapy in the treatment of neonatal jaundice. According to the National Center for Biotechnology Information (NCBI), around 13 million babies are afflicted with jaundice globally, each year. This in turn is expected to boost growth of the phototherapy equipment market size. However, high cost of the equipment is hindering growth of the market.

Some of the key players profiled in the study are Atom Medical Corporation, Natus Medical Incorporated, Daavlin, Phoenix Medical Systems Pvt. Ltd, Philips Lighting Holding B.V., Solarc Systems, Inc., and GE Healthcare, Inc.

Get up to 30% Discount on this Premium Report @:https://www.coherentmarketinsights.com/insight/request-discount/1177

Market Taxonomy:

The global phototherapy equipment market is segmented into devices, application, end user, and geography

On the basis of devices, the global phototherapy equipment market is segmented into:

On the basis of application, the global phototherapy equipment market is segmented into:

Apply Promo Code STAYHOME andGet Up to 30%Discount

Buy This Complete A Business Report:https://www.coherentmarketinsights.com/insight/buy-now/1177

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone: US +1-206-701-6702/UK +44-020 8133 4027Email:sales@coherentmarketinsights.com

Follow this link:

Phototherapy Equipment Market 2020 Size, Share, Analysis, Growth Driver and Industry Segments by 2027 KSU | The Sentinel Newspaper - KSU | The...

The use of biologic agents among patients with moderate to severe psoriasis infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), was associated with a lower risk for COVID-19-related hospitalization compared with patients who used non-biologic system agents, according to findings from a registry analysis published in the Journal of Allergy and Clinical Immunology.

There were 2 data sources reviewed in this registry-based study: the international Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 infecTion (PsoProtect) and the self-report patient-facing registry PsoProtectMe. The PsoProtect included clinician-reported diagnoses of confirmed or suspected COVID-19 in patients with psoriasis, whereas the patient-facing registry provided data on risk-mitigating behaviors.

There was a total of 374 clinician-reported patients with psoriasis and suspected/confirmed COVID-19 from 25 countries. Approximately 71% of these patients were receiving a biologic agent, whereas 18% of patients were receiving a non-biologic agent and 10% were receiving no systemic therapy for psoriasis. The majority of patients in the registry (93%) fully recovered from COVID-19. About 21% (n=77) of patients were hospitalized, and 2% (n=9) died.

An increased risk for hospitalization was associated with older age (multivariable-adjusted odds ratio [OR], 1.59 per 10 years; 95% CI, 1.19-2.13), male sex (OR, 2.51; 95% CI, 1.23-5.12), non-white ethnicity (OR, 3.15; 95% CI, 1.24-8.03), and comorbid chronic lung disease (OR, 3.87; 95% CI, 1.52-9.83).

Patients in the PsoProtect registry who used non-biologic systemic therapies were more frequently hospitalized compared with patients who received biologic agents (OR, 2.84; 95% CI, 1.31-6.18).

In the PsoProtectMe registry including 1626 patients from 48 countries who provided self-reported data, the researchers found lower levels of social isolation in patients who received non-biologic systemic therapy vs biologic agents (OR 0.68; 95% CI, 0.50-0.94).

A limitation of this study is its potential lack of generalizability, due to the inclusion of only patients with moderate to severe psoriasis and the high volume of patients from Spain, Italy, and the United Kingdom.

The investigators of this study emphasize that more data are necessary to clarify these observations before any recommendations for changes in clinical practice can be considered, adding that further investigation of the observed differential rate of hospitalization between different classes of biologics is warranted.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis insights from a global registry-based study. Published online October 16, 2020. J Allergy Clin Immunol. doi:10.1016/j.jaci.2020.10.007

Go here to see the original:

Biologic Agent Use Associated With Lower Hospitalization Risk for Patients With Psoriasis and COVID-19 - Dermatology Advisor

Psoriasis Treatment Market research report is the new statistical data source added by A2Z Market Research.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280493

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Sun Pharmaceutical Industries Ltd., Amgen Inc., Novartis AG, LEO Pharma A/S, Eli Lilly and Company, UCB S.A., Johnson and Johnson Services, Inc., CELGENE CORPORATION, Pfizer Inc.,, AbbVie Inc., Merck and Co., Inc.

The key questions answered in this report:

What will be the Market Size and Growth Rate in the forecast year?What are the Key Factors driving Psoriasis Treatment Market?What are the Risks and Challenges in front of the market?Who are the Key Vendors in Psoriasis Treatment Market?What are the Trending Factors influencing the market shares?What are the Key Outcomes of Porters five forces model?Which are the Global Opportunities for Expanding the Psoriasis Treatment Market?

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=280493

Global Psoriasis Treatment Market Segmentation:

Market Segmentation by Type:

TNF InhibitorsInterleukinsOthers

Market Segmentation by Application:

Hospital PharmaciesRetail PharmaciesOnline pharmacies

Regions Covered in the Global Psoriasis Treatment Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Psoriasis Treatment market.Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Psoriasis Treatment market.

Table of Contents

Global Psoriasis Treatment Market Research Report 2020 2026

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=280493

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

The rest is here:

Comprehensive Report on Psoriasis Treatment Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Sun Pharmaceutical Industries...

What are the emerging opportunities in the Chronic Plaque Psoriasis Therapeutics Market?

Currently, significant business sectors are going through changes. This has prompted huge benefits for a few and misfortunes for other people. To make the most out of the emerging chances, you can exploit the most granted Chronic Plaque Psoriasis Therapeutics market report. It offers nitty-gritty experiences into the market. This will doubtlessly manage their organizations in creating the following move over the impending industry quarters.

It must be noticed that the Chronic Plaque Psoriasis Therapeutics market is encountering unexpected ascent in reception by numerous new players (from MNCs to SMEs). It is because of the way that even with the market turbulences the Global market came out with solid numbers. With the new business running into the market, it is basic to stand apart from the group. The customers can undoubtedly accomplish this utilizing the means referenced in the Chronic Plaque Psoriasis Therapeutics market report.

What type of investigation is done in the Chronic Plaque Psoriasis Therapeutics market report?

Analysis of various socioeconomics for venturing into the market is important as it will hugely affect the development throughout the following coming years. The Chronic Plaque Psoriasis Therapeutics market report is planned subsequent to doing long periods of exploration and the information sifted through in the report was gathered from dependable sources, for example, government sites.

As the market is gigantic, it turns out to be imperative to comprehend the market from its underlying foundations. Get a superior perspective on the Chronic Plaque Psoriasis Therapeutics market through the data referenced in the committed areas of the report. With this, the customers likewise get a perspective on the business structure of the contenders.

What are the reasons that impact the growth of the Chronic Plaque Psoriasis Therapeutics Market?

As of late, the advanced transformation has pushed the associations in changing into a computerized business for coming to the intended interest group present over the globe. The Chronic Plaque Psoriasis Therapeutics market report shares the significance of neighborhood language, partners, and political situation that will drive the Global market higher than ever.

With the best possible comprehension of the Chronic Plaque Psoriasis Therapeutics market, the associations can hop onto the open doors that will bring productive outcomes. The customers can exploit the biggest in-house information base for taking the most effective actions. Likewise, the Chronic Plaque Psoriasis Therapeutics market report has committed segments covering the insights concerning the current market players. With the information on how they function and accomplish their objectives, your business can likewise be formed as needs be.

What type of analysis short-term or long-term is added in the Chronic Plaque Psoriasis Therapeutics Market report?

This is important to sidestep any negative circumstances that may affect the development of the organizations. In addition, the associations need to comprehend Porters five powers that shape the market elements. In the event that the customers wish to add or eliminate the names of the organizations, it tends to be done, to suit the desires for the clients, for accomplishing long-haul objectives. SWOT investigation helps in uncovering the qualities and shortcomings of the business. The PESTLE investigation helps in checking the outer elements that shape the market overall. Subsequently, for making a name in the Chronic Plaque Psoriasis Therapeutics market, it gets important to get thought from both SWOT and PESTLE investigations.

The Chronic Plaque Psoriasis Therapeutics market report likewise brushes over the significance of language and partners for the smooth working of the associations. Thusly, the customers are stacked with data and steps and are prepared to move into the market for accomplishing the ideal objectives.

About Us:

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Reports provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

The rest is here:

Chronic Plaque Psoriasis Therapeutics Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2027 - Cheshire Media

Psoriasis is an autoimmune condition and cannot be cured completely. The current treatment methods, to an extent, effectively work in controlling the disease. Hence, the opportunities for consumption remains worthy for players in the globalpsoriasis treatment marketin the coming years. However, with time, companies would want to stay ahead in the league and hence are working on developing drugs that are more effective. The current drug pipeline appears to be promising and any launch in the next few years will have a significant impact on the growth of the global psoriasis treatment market.

Transparency Market Research has recently published a report on the global psoriasis treatment market. It states that the market is expected to grow at a decent rate of 5.10% CAGR during 2016 to 2024. The potential players in the global psoriasis treatment market include LEO Pharma, AbbVie, AstraZeneca, Pfizer, and Biogen.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17960

Rise in Psoriasis Cases to Favor Growth

The overall number of cases of psoriasis has steadily increased. While the incidence of the disease is on the rise due to several factors that trigger gene mutation such as pollution and lifestyle habits. At the same time, the general awareness among the public about the disease is considered to be the larger reason for the rise in number of cases. With internet and social media presence, healthcare organizations and governments have been able to conduct awareness campaigns that reach out to the people. As a result, people have realized the importance of early diagnosis and timely treatment for the disease. This has been one of the largest factors for growth in the global psoriasis treatment market.

While there has been general awareness among the public, governments across the world have taken initiatives to help people suffering from these conditions, especially in the rural areas. Consistent campaigns and efforts to ensure people from the rural and deeper areas where the access to healthcare is poor, has raised the demand for products in the global psoriasis treatment market.

Request for Analysis of COVID19 Impact on Psoriasis Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=17960

Favorable Healthcare System to Augment Growth in North America

Undoubtedly the developed healthcare system in North America, especially the United States, favors growth for the global psoriasis market. The regulated healthcare system coupled with organized policies that aid in diagnosing diseases and treating them on time have been of solid support to all healthcare markets. At the same time, the buzzing pharmaceutical business environment keeps the North American region sound for business. These aspects have a substantial impact on the growth of the global psoriasis treatment market.

Besides North America, Europe and Asia Pacific will also remain important for players in the global psoriasis treatment market. Companies will be looking to explore business potential in new areas in the coming years to be able to expand and sustain in the business.

Buy Psoriasis Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=17960&ltype=S

The global psoriasis treatment is segmented based on

Drug Class

Route of Administration

Distribution Chanel

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the original post:

Psoriasis Treatment Market expected to grow at a decent rate of 5.10% CAGR during 2016 to 2024 - The Haitian-Caribbean News Network

This report gives a vital investigation of the Global Plaque Psoriasis Treatment market and the development gauges for the conjecture time frame. This report likewise gives market estimating and figures to the Global Plaque Psoriasis Treatment market.

Some of the players in Plaque Psoriasis Treatment Market areNovartis AG (Switzerland),AbbVie Inc.(U.S),Amgen, Inc. (U.S),Johnson & Johnson (U.S),Eli Lilly and Company (U.S),Celgene Corporation (U.S),Sun Pharmaceuticals Industries Ltd. (India)

Request free sample copy of thishttps://www.precisionbusinessinsights.com/request-sample?product_id=23496

The most recent market report on Plaque Psoriasis Treatment industry offers a top to bottom investigation of this business vertical including key data concerning industry expectations, transcendently showcase inclinations, advertise size, piece of the overall industry, present valuation, and benefits estimations for the gauge time frame. The concise data in regards to the business additionally breaks down and clarifies the Plaque Psoriasis Treatment market development rate in the conjecture course of events, prompted by specific impetuses, a substance of which has been given in this exploration report related to the essential difficulties and development prospects present in the business.

Statistical surveying Place has included a report, Global Plaque Psoriasis Treatment Market Research Report 2020-2026 incorporates a careful investigation of the Plaque Psoriasis Treatment advertise in the anticipated period. Worldwide Plaque Psoriasis Treatment market report offers the most recent industry patterns, mechanical developments and figure showcase information. A profound jump perspective on Plaque Psoriasis Treatment industry dependent on market size, Plaque Psoriasis Treatment development, advancement plans, and openings is offered by this report. The estimate advertises data, SWOT examination, Plaque Psoriasis Treatment hindrances, and attainability study are the fundamental angles broke down in this report.

Request Customization athttps://www.precisionbusinessinsights.com/request-customisation?product_id=23496

Key Features of the Report:

There are 10 Chapters to deeply display the Plaque Psoriasis Treatment market.Chapter 1 to analyze the top manufacturers of Plaque Psoriasis Treatment, with sales, revenue and price of Plaque Psoriasis Treatment in 2020 and 2026.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2026.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Plaque Psoriasis Treatment, for each region, from 2020 and 2026.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2020 and 2026.

Chapter 10 Plaque Psoriasis Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 and 2026.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our Plaque Psoriasis Treatment is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Read more from the original source:

Plaque Psoriasis Treatment Market to receive overwhelming hike in Revenues by 2026 Novartis AG (Switzerland),AbbVie Inc.(US),Amgen, Inc. (US) -...

A variety of health issues can cause bumps to form on the scalp, including folliculitis, acne, head lice, and eczema.

Many causes of bumps in this area are harmless, but receiving a prompt diagnosis and treatment can address any concerns and resolve the issue quickly.

In this article, learn about the health conditions that can lead to bumps on the scalp and when to contact a doctor.

Acne that forms on the scalp can be similar to acne in other areas. A person may have raised bumps, whiteheads, or blackheads, which may be itchy, sore, or tender.

Scalp acne occurs when pores or hair follicles become clogged with dead skin cells or oil. If a person has oily hair or adds certain products to their hair, they might be more susceptible to scalp acne.

Factors that may contribute to scalp acne include:

If scalp acne develops consistently, wash the hair more thoroughly, and try hypoallergenic hair products.

If the issue persists or gets worse, contact a dermatologist for specific guidance.

Learn more about treatments for scalp acne.

Folliculitis is a common infection that develops in hair follicles. It can look similar to acne and causes raised, round, inflamed, and itchy bumps.

The infection develops when bacteria enter damaged follicles, and the underlying cause may involve:

To relieve any pain and help the skin heal, apply a warm compress to the area three or four times a day, for 20 minutes at a time.

If the issue worsens, or the cause is unclear, contact a dermatologist.

Itchiness is the most common symptom of head lice, but bumps on the scalp can also indicate their presence.

Have someone closely examine the area for white eggs or moving lice.

Treatment for head lice typically involves using medicated shampoo and combing the area to kill and remove the bugs and their eggs.

Learn more about treatment for head lice here.

There are many types of eczema, and two that can affect the scalp include:

This type of eczema can develop anywhere on the body, including the scalp.

It causes the skin to become inflamed. On a person with darker skin, the affected areas may become darker, grayish, or purplish. On a person with lighter skin, the areas may redden.

In children, it typically affects the hands, backs of the knees, insides of the elbows, scalp, and face.

Adults with this chronic form of eczema on the scalp may notice color changes such as redness, as well as swelling and greasy scaling.

Beyond the scalp, seborrheic dermatitis can affect the:

For eczema on the scalp, try medicated shampoos, creams, or ointments.

Learn more about the treatments for scalp eczema.

Contact dermatitis occurs when the skin comes into contact with an allergen or irritant.

When this issue develops on the scalp, hair products containing fragrances or specific chemicals may be responsible.

When the scalp reacts to an irritant or allergen, such as a chemical, it can cause itchiness, a burning sensation, and sometimes blistering.

The reaction can occur within minutes of contact with the irritant.

It is important to avoid further contact with products that may be responsible. Also, a doctor may prescribe topical steroids.

These fluid-filled cysts most commonly develop on the scalp. They form in the hair follicles and contain excess keratin, a protein that occurs in the hair, nails, and skin.

The cysts are typically large and smooth, and they may be tender. Sometimes, more than one occurs in one area.

Pilar cysts typically go away on their own. To reduce the swelling and any tenderness, try applying a warm, clean washcloth to the area.

If a cyst becomes infected, a doctor may prescribe antibiotics. Also, a doctor may recommend the surgical removal of a cyst.

Learn more about the treatments for pilar cysts here.

Hives are a rash consisting of itchy, raised bumps. The rash forms as part of an allergic response, and it can affect any part of the body, including the scalp.

Hives usually go away on their own within a few days. However, a doctor can prescribe antihistamines or corticosteroids.

Learn more about the treatments for hives.

Ringworm is a fungal infection of the skin, and it can form on the scalp. Healthcare professionals may refer to this as tinea capitis.

Symptoms include:

Tinea capitis is more common in children than adults.

Creams, powders, and lotions do not work for ringworm on the scalp. Instead, a doctor prescribes an oral antifungal medication that a person must take for 13 months.

Melanomas can appear on the scalp, as can:

Unlike the other bumps or blemishes described above, lumps caused by skin cancer continue to change shape and size.

If any bumps on the scalp may indicate cancer, contact a dermatologist immediately.

After making a diagnosis, the doctor will describe the treatments, including surgical and nonsurgical options.

A person can treat most of the health issues that cause bumps on the scalp at home, with care strategies, such as using warm compresses or switching shampoos, and over-the-counter medications.

However, contact a healthcare provider about any unusual growths or symptoms of ringworm or atopic dermatitis.

Also, if any scalp issue persists or worsens, consult a dermatologist.

Bumps on the scalp can result from a variety of health issues, such as acne, eczema, psoriasis, pilar cysts, hives, or ringworm.

Some causes of bumps, such as skin cancer, require urgent medical attention. But often, a person can address the issue at home.

If any lump, bump, or blemish on the scalp is concerning, or if home care is ineffective, contact a dermatologist or another healthcare professional.

See more here:

Bumps on the scalp: Causes, symptoms, and treatments - Medical News Today

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a key opinion leader discussion on the unmet need in psoriasis and atopic dermatitis, including the potential of EDP1815 to serve as a new therapeutic option for patients living with mild to moderate disease. The event will be held virtually on Thursday, October 22, 2020 from 9:00 a.m. to 10:30 a.m. ET.

As part of the event, Benjamin Ehst, M.D., Ph.D., Board-certified Dermatologist, Investigator and Clinical Associate Professor with the Oregon Medical Research Center, will discuss the current treatment landscape and unmet need in psoriasis. Additionally, Evelo management will host a panel discussion with Dr. Ehst to review the opportunity for EDP1815 in atopic dermatitis. Evelos management team will also review the design of its recently initiated Phase 2 trial in psoriasis and provide an overview of the clinical data generated with EDP1815 to date, as well as the Companys platform and upcoming milestones.

To access the live event, please dial (866) 795-3242 (domestic) or (409) 937-8909 (international) and refer to conference ID 1552379. A live webcast of the event will also be available under News and Events in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Dr. Benjamin EhstDr. Benjamin Ehst is a board-certified dermatologist and clinical associate professor at Oregon Medical Research Center.

Dr. Ehst spent his early career at Oregon Health & Science University (OHSU) as an associate professor in the Department of Dermatology. He honed his specialty in psoriasis as a member of the Center of Excellence in Psoriasis and Psoriatic Arthritis, eventually taking over as co-director of the multidisciplinary center. Additionally, Dr. Ehst organized a specialty clinic caring for skin-related issues in HIV-infected individuals.

Alongside patient care and teaching, Dr. Ehst began his work in clinical research while at OHSU, acting as lead investigator for studies on treatments for skin diseases such as atopic dermatitis, psoriasis, granuloma annulare, actinic keratosis and melanoma.

Dr. Ehst earned his undergraduate degree from the University of Chicago and his medical and doctoral degrees at the University of Minnesota in a combined Medical Scientist Training Program. He received his residency training in Dermatology at the Johns Hopkins Hospital in Baltimore and solidified his interest in medical practice and clinical research while studying the immune response to malaria at the Hopkins Bloomberg School of Public Health.

About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The companys first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit http://www.evelobio.com and engage with Evelo on LinkedIn.

ContactEvelo BiosciencesJessica Cotrone, 978-760-5622jcotrone@evelobio.com

Go here to read the rest:

Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for...

BARCELONA, Spain, Oct. 13, 2020 /PRNewswire/ -- Almirall, S.A. (ALM)announced today that it has signed an agreement with the French Authorities to make the biologic treatment ILUMETRI (tildrakizumab), a high-affinity IL-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy.

The agreement has been signed after the Commission of Transparency of the Haute Autorit de Sant(HAS), the French National Health Authority, provided a favourable opinion for the reimbursement in France of ILUMETRI (tildrakizumab) on June 3rd and considered the actual benefit (Service Mdical Rendu or SMR) as "important". Theprevalenceof chronic plaque psoriasis among theFrenchpopulation is around 5,6%.

Following the publication of the agreement in the French Official Journal, Ilumetri (tildrakizumab) will be included in the list of reimbursable medicines by the social insurance for the treatment of adults with severe chronic plaque psoriasis.

"Today's announcement represents great news for those patients with severe psoriasis across France who can count on a safe and convenient biological treatment for their condition. Ilumetri provides sustained high efficacy and safety, and improves patients' quality of life"said Alfredo Barn, Chief Commercial Officer of Almirall. "We are glad we could collaborate with French authorities to find an agreement to provide sustainable access to an additional biologic treatment option for patients suffering from this skin disease through a national reimbursement agreement," he added.

Ilumetri (tildrakizumab) is the first biologic marketed by Almirall and constitutes an important step forward in the treatment of moderate-to-severe chronic plaque psoriasis. Since its approval by the European Commission in November of 2018, the product has been,offering a decisive benefit to patients as it has the longest efficacy and safety data among the IL23p19s.Ilumetri is reimbursed in 10 countries around Europe, including recent agreements in Belgium and Italy.

Tildrakizumab is administered by subcutaneous injection. Its dosing regimen, with lower frequency of injections, only 4 injections per year during maintenance1, offers convenience and quality of life for patients, potentially achieving an improved treatment satisfaction and improving adherence to treatment.

References

SOURCE Almirall, S.A. (ALM)

Original post:

Almirall, SA (ALM) announces approval of the reimbursed price for Ilumetri (tildrakizumab) in France for the treatment of adult patients with severe...